Compare · SYM vs TMO
SYM vs TMO
Side-by-side comparison of Symbotic Inc. (SYM) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYM and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $197.88B, about 8.0x SYM ($24.86B).
- TMO has been more active in the news (9 items in the past 4 weeks vs 6 for SYM).
- Both have 25 recent analyst ratings on file.
- Company
- Symbotic Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $24.86B
- $197.88B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest SYM
- Symbotic Announces Date for Reporting Third Quarter Fiscal Year 2026 Financial Results
- Director Krasnow Todd sold $259,566 worth of shares (5,367 units at $48.36) as part of a pre-agreed trading plan, disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan and acquired 2,000 shares as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
- Director Kane Charles disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan, acquired 2,000 shares as part of a pre-agreed trading plan and sold $89,800 worth of shares (2,000 units at $44.90) as part of a pre-agreed trading plan, decreasing direct ownership by 85% to 89,852 units (SEC Form 4)
- Chief Strategy Officer Boyd William M Iii sold $230,960 worth of shares (5,115 units at $45.15) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 57,112 units (SEC Form 4)
- Symbotic Announces Acquisition of ARMS Innovations, Advancing a New Era of Warehouse Operations Optimization
- SEC Form 144 filed by Symbotic Inc.
- Director Kane Charles disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan, acquired 2,000 shares as part of a pre-agreed trading plan and sold $91,980 worth of shares (2,000 units at $45.99) as part of a pre-agreed trading plan, decreasing direct ownership by 85% to 89,852 units (SEC Form 4)
- Director Krasnow Todd sold $94,604 worth of shares (2,000 units at $47.30) as part of a pre-agreed trading plan, disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan and acquired 2,000 shares as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Symbotic Inc.
- SEC Form SD filed by Symbotic Inc.
Latest TMO
- Thermo Fisher Scientific Announces Quarterly Dividend
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Keith R. Alexandra
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- Bernstein resumed coverage on Thermo Fisher with a new price target
- SEC Form 11-K filed by Thermo Fisher Scientific Inc
- Piper Sandler initiated coverage on Thermo Fisher with a new price target